Skip to Content

'
Rosemarie E Schmandt, Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Bio Statement:

Rosemarie Schmandt, Ph.D. obtained her degree in Clinical Biochemistry at the University of Toronto in 1996 and joined the University of Texas, M.D. Anderson Cancer Center in the Department of Gynecologic Oncology in the fall of 1999.    Dr. Schmandt is a member of the graduate faculty for The University of Texas Graduate School of Biomedical Sciences. She is also a member of the American Association for Cancer Research and an associate member of the Society of Gynecologic Oncologists.  

 

Research Interests

Research Interests:

Dr. Schmandt’s research has focused on the identification of molecular targets for the more effective treatment of ovarian cancer. In additions, her laboratory is involved in understanding the underlying molecular mechanisms by which diet and physical activity reduce the incidence and recurrence of gynecologic tumors resulting from chronic stress and obesity. Studies include:

  • Characterization of the effects of diet, physical activity and antidepressants on the prevention of chronic stress-induced tumor growth.
  • Identification of relevant growth inhibitory signaling pathways common to diet, exercise and stress-reducing drugs and behaviors
  • Characterization of novel chemopreventive agents targeting these pathways
  • Development and characterization of obese mouse models of ovarian and endometrial cancer recurrence
  • Characterization of conditional knock out mouse models of endometrial cancer (PTEN, Msh2)

In collaboration with the MDACC SPORE in Ovarian Cancer

  • Identification and characterization of PFDN4 and PVT1 and other novel therapeutic targets for the more effective treatment of ovarian cancer.

Education & Training

Degree-Granting Education

1996 University of Toronto, Toronto, Ontario, Canada, PHD, Clinical Biochemistry
1989 University of Toronto, Toronto, Ontario, Canada, MS, Clinical Biochemistry
1985 Laurentian University, Sudbury, Ontario, Canada, BS, Biochemistry

Postgraduate Training

1/1999-8/1999 Postdoctoral Fellowship, Hospital for Sick Children, Arthur and Sonia Labatt Brain Tumour Research Center, Toronto, Ontario, Canada, Dr. C. Jane McGlade
1/1996-12/1998 Medical Biophysics, University of Toronto, Department of Medical Biophysics, AMGEN Institute, Toronto, Ontario, Canada, Dr. C. Jane McGlade, PhD
1/1996-12/1998 Research Fellowship, Medical Biophysics, AMGEN Research Institute/Ontario Cancer Institute Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada, Dr. C. Jane McGlade

Experience/Service

Academic Appointments

Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine - Research, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/1999-9/2008
Assistant Biologist, Department of Gynecologic Medical Oncology - Research, Division of Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/1999-9/2008

Honors and Awards

1998 MRC Postdoctoral Fellowship
1994 Department of Clinical Biochemistry Research Award, Ph.D.
1994 Genesis Research Foundation Studentship
1994 University of Toronto Open Scholarship
1991 Department of Obstetrics and Gynecology Research Award
1991 Ontario Graduate Scholarship
1990 MRC Studentship
1990 University of Toronto, Special Top-up Award
1989 Ontario Graduate Scholarship
1988 MRC Studentship
1987 Connaught Fellowship
1985 Honours B.Sc., Biochemistry
1985 INCO Reserved Scholarship
1985 NSERC Summer Studentship
1984 Laurentian University Faculty Scholarship (Biochemistry)
1983 CIC Silver Medal (Biochemistry)

Selected Publications

Peer-Reviewed Original Research Articles

1. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer. Int J Gynecol Cancer. e-Pub 3/19/2014. PMID: 24651628.
2. Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, Lu KH. Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy. Mol Cancer Ther 12(12):2847-56, 12/2013. e-Pub 9/2013. PMCID: PMC3883498.
3. Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol 209(1):24.e1-24.e12, 7/2013. e-Pub 3/15/2013. PMCID: PMC3819145.
4. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 123(5):2119-30, 5/1/2013. e-Pub 4/15/2013. PMCID: PMC3635722.
5. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):809-20, 2/15/2013. e-Pub 1/23/2013. PMCID: PMC3577959.
6. Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, Lu K, Kolonin MG. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res 18(3):771-82, 2/1/2012. e-Pub 12/13/2011. PMCID: PMC3481843.
7. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 205(6):518-25, 12/2011. e-Pub 6/7/2011. PMID: 21802066.
8. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):176-82, 2/2010. e-Pub 2/16/2010. PMCID: PMC3155813.
9. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 Immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 101(17):1193-205, 9/2/2009. e-Pub 7/29/2009. PMCID: PMC2736292.
10. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15(11):3770-80, 6/1/2009. e-Pub 5/26/2009. PMCID: PMC2752981.
11. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 15(9):2971-8, 5/1/2009. e-Pub 4/21/2009. PMCID: PMC2743312.
12. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641-2288, 12/18/2008. PMCID: PMC2710981.
13. Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, Smith-McCune K, Fishman D, Gray JW, Mills GB. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol 2(2):164-81, 8/2008. e-Pub 5/10/2008. PMCID: PMC2598416.
14. Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 26(4):404-9, 10/2007. PMID: 17885490.
15. Ishiyama S, Matsueda S, Jones LA, Efferson C, Celestino J, Schmandt R, Ioannides CG, Tsuda N, Chang DZ. Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites. Int J Oncol 30(4):889-98, 4/2007. PMID: 17332928.
16. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757-68, 2/2007. PMID: 17308118.
17. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5(12):1708-13, 12/2006. e-Pub 12/30/2006. PMID: 17106249.
18. Landen CN, Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98(21):1558-70, 11/2006. PMID: 17077358.
19. Merritt WM, Thaker PH, Landen CN, Jr, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther 5(10):1357-60, 10/2006. e-Pub 10/31/2006. PMID: 16969087.
20. Nanjundan M, Zhang F, Schmandt R, Smith-McCune K, Mills GB. Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions. Oncogene 26(18):2574-84, 10/2006. e-Pub 10/30/2006. PMID: 17072347.
21. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 5(9):1136-41, 9/2006. e-Pub 9/28/2006. PMID: 16855388.
22. Halder J, Kamat AA, Landen CN, Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12(16):4916-24, 8/2006. PMID: 16914580.
23. Han LY, Landen CN, Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. J Clin Oncol 24(5):755-61, 2/2006. e-Pub 12/27/2005. PMID: 16380413.
24. Halder J, Landen CN, Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 11(24 Pt 1):8829-36, 12/2005. PMID: 16361572.
25. Landen CN, Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65(15):6910-8, 8/2005. PMID: 16061675.
26. Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 95(1):32-6, 10/2004. PMID: 15385107.
27. Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13(5):748-52, 5/2004. PMID: 15159305.
28. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-300, 5/2004. PMID: 15161682.
29. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 90(3):529-36, 9/2003. PMID: 13678720.
30. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98(4):758-64, 8/2003. PMID: 12910520.
31. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Jr, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90(1):44-50, 7/2003. PMID: 12821340.
32. Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH. beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 88(3):363-8, 3/2003. PMID: 12648588.
33. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 36(2):53-9, 2/2003. PMID: 12557260.
34. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61(15):5895-904, 8/2001. PMID: 11479231.
35. Mills GB, Schmandt R, Gershenson D, Bast RC. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? Clin Cancer Res 5(9):2286-8, 9/1999. PMID: 10499594.
36. Schmandt R, Liu SK, McGlade CJ. Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells. Oncogene 18(10):1867-79, 3/1999. PMID: 10086341.
37. Verdi JM, Schmandt R, Bashirullah A, Jacob S, Salvino R, Craig CG, Program AE, Lipshitz HD, McGlade CJ. Mammalian NUMB is an evolutionarily conserved signaling adapter protein that specifies cell fate. Curr Biol 6(9):1134-45, 9/1996. PMID: 8805372.
38. Schmandt R, Shi Y, Mills G. What contributes to ovarian cancer cell growth? Contemporary OB/GYN 81-92, 1995.
39. Hogg D, Guidos C, Bailey D, Amendola A, Groves T, Davidson J, Schmandt R, Mills G. Cell cycle dependent regulation of the protein kinase TTK. Oncogene 9(1):89-96, 1/1994. PMID: 8302607.
40. Schmandt R, Hill M, Amendola A, Mills GB, Hogg D. IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression. J Immunol 152(1):96-105, 1994. PMID: 8254211.
41. Schmandt R, Mills GB. Genomic components of carcinogenesis. Clin Chem 39(11 Pt 2):2375-85, 11/1993. PMID: 8222249.
42. Mills GB, Schmandt R, Gibson S, Leung B, Hill M, May C, Shi YF, Branch DR, Radvanyi L, Truitt KE. Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. Semin Immunol 5(5):345-64, 10/1993. PMID: 8260651.
43. Mills GB, Arima N, May C, Hill M, Schmandt R, Li J, Miyamoto NG, Greene WC. Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. Int Immunol 4(11):1233-43, 11/1992. PMID: 1472476.
44. Mills GB, Schmandt R, McGill M, Amendola A, Hill M, Jacobs K, May C, Rodricks AM, Campbell S, Hogg D. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem 267(22):16000-6, 8/1992. PMID: 1639825.
45. Schmandt R, Fung M, Arima N, Zhang N, Leung B, May C, Gibson S, Hill M, Green W, Mills GB. T-lymphocyte proliferation: tyrosine kinases in interleukin 2 signal transduction. Baillieres Clin Haematol 5(3):551-73, 7/1992. PMID: 1457964.
46. Fung MR, Scearce RM, Hoffman JA, Peffer NJ, Hammes SR, Hosking JB, Schmandt R, Kuziel WA, Haynes BF, Mills GB, et al. A tyrosine kinase physically associates with the beta-subunit of the human IL-2 receptor. J Immunol 147(4):1253-60, 8/1991. PMID: 1869821.
47. Mills GB, Zhang N, Schmandt R, Fung M, Greene W, Mellors A, Hogg D. Transmembrane signalling by interleukin 2. Biochem Soc Trans 19(2):277-87, 4/1991. PMID: 1889610.

Invited Articles

1. Mills GB, Schmandt R, Gershenson DM, Bast RC. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? Clin Cancer Res 5:2286-2288, 3/1999.

Abstracts

1. Iglesias, DA, Zhang Q, Co NN, Schmandt R, Lu KH. The effect of Metformin on cell proliferation in PTEN null endometiral cancer cell lines. SGO 42nd Annual Meeting on Women's Cancer, Orlandi, FL, 3/2011.
2. Armaiz-Pena G, Mangala LS, Han LY, Lin YG, Schmandt R, Sanguino AM, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth through a Src-dependent mechanism in a mouse model of ovarian cancer. The 15th Annual Meeting of the Psychoneuroimmunology Research Society, Madison, WI, 2008.
3. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Pennacchio LA, Cheng JF, Zeidan A, Wang H, Gray JW, Mok S, S Birrer MJ, Lopez-Berestein G, Coleman RI, Bar-Eli M, Sood AK. Decreased expression of RNA interference machinery, dicer and drosha, may impact the efficacy of RNAi-targeted therapies in ovarian cancer. The 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, 2008.
4. Schmandt R, Sook AK, Lutgendorf S, Mangala LS, Armaiz-Pena G. Exercise therapy for ovarian cancer: How does exercise counteract stress-induced tumor growth?. 15th Annual Meeting of the Psychoneuroimmunology Research Society, Madison, WI, 2008.
5. Merritt WM, Lin YG, Spannuth WA, Kamat AA, Han LY, Landen CN, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Novel approach to anti-angiogenic therapy through interleukin-8 silencing in ovarian cancer. The 39th Annual Meeting of the Society of Gynecologic Oncologists, Tampa, FL, 2008.
6. Lu C, Bonome T, Kamat A, Lin Y, Merritt W, Schmandt R, Coleman R, Gershenson DM, Jaffe R, Birrer M, Sood A. Alterations in endothelial cell gene expression in human ovarian cancer. National Institutes of Health 15th SPORE Investigators Workshop, Baltimore, MD, July, 2007:112 Abstract #217, 2007.
7. Guan Y, Kuo W, Stillwell J, Takano H, Lapuk A, Fridyand J, Mao J, Yu M, Miller M, Santos J, Kalloger S, Carlson J, Ginzinger, Celniker S, Huntman D, Sood, A, Schmandt R, Gray J. PVT1 as a therapeutic target in ovarian cancer. National Institutes of Health 15th SPORE Investigators Workshop, Baltimore, MD, July, 2007:112 Abstract #215, 2007.
8. Bennett M, Han LY, Merritt W, Lin Y, Gray JW, Gershenson DM, Sood AK, Schmandt R. Targeting cytoskeletal assembly as a strategy to overcome taxane resistance in ovarian cancer. Society of Gynecologic Oncologists 36th Annual Meeting, San Diego, CA, 2007.
9. Bennett M, Clifford SL, Thornton A, Broaddus RR, Gray JW, Jiang F, Lu KH, Sood AK, Gershenson DM, Schmandt RE. BRK/PTK6 is frequently amplified and promotes tumor growth in ovarian carcinoma. Society of Gynecologic Oncologists 35th Annual Meeting, Palm Springs, CA, 2006, 2006.
10. Schmandt RE. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. American Association for Cancer Research (AACR):#3771, 2006.
11. Sood AK, Fletcher MS, DeYoung B, Gruman LM, Thaker P, Landen C, Schmandt R, Gershenson DM. Biological and Clinical Significance of Focal Adhesion Kinase (FAK) in Ovarian Cancer. University of Texas M.D. Anderson Cancer Center, Houston, TX and University of Iowa Hospitals and Clinics, Iowa City, IA SGO 34th Annual Meeting, Miami Beach, Florida, 10/2005.
12. Han LY, Landen C, Kamat A, Schmandt R, Mueller P, Gershenson DM, Sood AK. Preoperative Serium Tissue Factor (TF): An Independent Predictor of Poor Outcome in Ovarian Carcinoma. Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, Texas SGO 34th Annual Meeting, Miami Beach, Florida, 10/2005.
13. Sood AK, Landen C, Bhatty R, Thaker P, Schmandt R, Gershenson DM, Lutgendorf S. Stress Hormone Medicated Invasion of Ovarian Cancer Cells. Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, Texas SGO 34th Annual Meeting, Miami Beach, Florida, 10/2005.
14. Oh JC, Slomovitz BM, Broaddus RR, Gershenson DM, Burke TW, Schmandt R, Lu KH. Endometrial cancer in patients under 50: 161 patients from a single institution. Society of Gynecologic Oncologists Annual Meeting. New Orleans, LA, 8/2003.
15. Slomovitz BM, Broaddus RR, Thornton AD, Oh JC, Celestino J, Schmandt R, Burke TW, Gershenson DM, Lu K. Gleevec (Imatinib Mesylate) targeted kinases are activated in most endometrial cancers. Society of Gynecologic Oncologists Annual Meeting. New Orleans, LA, 8/2003.
16. Oh J, Broaddus R, Totolero G, Gershenson DM, Burke TW, Schmandt R, Lu K. Insulin-like growth factors and endometrial cancer. Proceedings of the ASCO 21:879, 8/2002.
17. Schmandt RE, Clifford SL, Lee J, Lillie J, Deavers M, Shaw P, Jung M, Levenback C, Bast R, Mills G, Gershenson DM, Lu KH. Differential expression of the secreted protease inhibitor, HE4, in epithelial ovarian cancer. Gynecol Oncol 80:319, 3/2001.
18. Lu KH, Malpica AM, Bodurka-Bevers D, Shvartsman HS, Schmandt RE, Thornton A, Deavers MT, Silva EG, Gershenson DM. Immunohistochemical analysis of low grade serous ovarian carcinomas. Gynecol Oncol 80(2):320, 3/2001.
19. Shvartsman HS, Lu KH, Clifford SL, Lee J, Lillie J, Deavers M, Jung M, Bast R, Mills G, Gershenson DM, Schmandt RE. Overexpression of NES-1 in epithelial ovarian cancer. Gynecol Oncol 80:319, 3/2001.
20. Marshall WS, Schmandt R, Augustine K. Facilitating the functional characterization of genes using oligonucleotides. Nature Biotechnology: Antisense 98: Oligonucleotide strategies for treating the Molecular Basis of Disease. London, UK,, 9/1998.
21. Schmandt R, Liu S, Jacob S, Wolting C, McGlade J. Identification and characterization of a novel Shc binding protein, PAL. Tyrosine Phosphorylation in Signal Transduction. LaJolla, CA. 9/1997.
22. McGlade J, Jacob S, Dho S, French M, Schmandt R. The numb PTB(PI) Domain: Characterization of binding specificity and identification of a novel numb binding protein. Tyrosine Phosphorylation in Signal Transduction. LaJolla, CA, 9/1997.
23. Schmandt R, Liu S, Jacob S, Wolting C, McGlade J. Identification and characterization of a novel Shc binding protein, SBP5.2. Keystone Symposium, Keystone, CO, 1996.
24. McGlade J, Schmandt R, Liu S, Larose L, Jacob S, Wolting C, Dho S. Identification and characterization of Shc associated proteins. Keystone Symposium.Taos, NM, 1996.
25. Mills GB, Schmandt R, Gibson S, Leung B, Shi Y-F, Radvanyi L, Branch D. Transmembrane signaling by Interleukin 2: Mechanisms and cloning of unique kinases. Harden Conference, 4/1992.
26. Schmandt R Mills GB. Characterization of a unique kinase TTK. 2nd Eastern Canadian Conference on Development and Cancer. Montreal, PQ, 3/1991.
27. Schmandt R, Hogg D, Mills G. Characterization of unique kinase, TTK. Signal Transduction in normal and cancer cells. Banff, AB, 3/1991.
28. Mills GB, Schmandt R, Campbell S, Hill M, May C, Hogg D, Shaw P, Buckman R, Osborne R, Rosen B, Murphy J, DePetrillo AD. Expression of a unique tyrosine/threonine kinase by malignant ovarian epithelial cells. SOGC, 3/1991.
29. Mills GB, Hashimoto S, Hurteau J, Schmandt R, Rosen B, Murphy J, Osborne R, DePetrillo A, Shaw P, Buckman R. Growth regulation of ovarian cancer cells. Proceedings: Biology and therapy of ovarian cancer, 3/1991.

Book Chapters

1. Mills GB, Gibson S, Schmandt R, Fang XJ, Weiner JR. Signal transduction. In: Transplantation Biology: Cellular and Molecular Aspects. Transplantation Biology: Cellular and Molecular Aspects, 1996.
2. Schmandt R, Hogg D, Mills GB. TTK (Serine), threonine, tyrosine kinase (human). In: Protein Kinase Factsbook. Protein Kinase Factsbook, 368-370, 1994.
3. Mills GB, Hashimoto S, Hurteau J, Schmandt R, Campbell S, May C, Hill M, Shaw P, Buckman R, Hogg D. Regulation of growth of human ovarian cancer cells. In: Ovarian Cancer 2-Biology Diagnosis and Management. Ovarian Cancer 2-Biology Diagnosis and Management, 127-143, 1992.

Grant & Contract Support

Title: Project 1: Metformin for the chemoprevention of endometrial cancer in obese, insulin-resistant women
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: K. Lu
Duration: 9/2010 - 8/2015
 
Title: Entertainment Industry Fund
Funding Source: Blanton-Davis Ovarian Cancer Research Program
Role: Research Scientist
Duration: 5/1/2009 - present
 
Title: Exercise Therapy for Ovarian Cancer: How does exercise counteract stress-induced tumor growth?
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 5/2009 - 4/2011
 
Title: Destabilizing the Microtubule Cytoskeleton in Ovarian Carcinoma: PFDN4-siRNA Therapy as an Alternative to Taxanes
Funding Source: The Bettyann Asche Murray Development Award for Ovarian Cancer Research
Role: Principal Investigator
Duration: 4/1/2007 - present
 
Title: Does exosomal miR21 contribute to ovarian cancer progression in the omentum?
Funding Source: NIH/NCI
Role: Principal Investigator

Last updated: 6/25/2014